Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) EBIT Margin (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of EBIT Margin data on record, last reported at 3249.27% in Q4 2025.

  • For Q4 2025, EBIT Margin fell 323358.0% year-over-year to 3249.27%; the TTM value through Dec 2025 reached 621.13%, down 64344.0%, while the annual FY2025 figure was 621.13%, 64344.0% down from the prior year.
  • EBIT Margin reached 3249.27% in Q4 2025 per TRDA's latest filing, down from 2915.18% in the prior quarter.
  • Across five years, EBIT Margin topped out at 56.42% in Q2 2024 and bottomed at 3249.27% in Q4 2025.
  • Average EBIT Margin over 3 years is 731.33%, with a median of 56.29% recorded in 2023.
  • Peak YoY movement for EBIT Margin: skyrocketed 14612bps in 2024, then crashed -323358bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 11.72% in 2023, then crashed by -234bps to 15.69% in 2024, then tumbled by -20612bps to 3249.27% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 3249.27% in Q4 2025, 2915.18% in Q3 2025, and 2402.51% in Q2 2025.